Skip to content

[Esketamine alleviates depression-like behaviors in mice with chronic restraint stress by activating glutamatergic neurons in the medial prefrontal cortex].

Zhuoning Zhang, Xinyu Hao, Fuyang Cao, Yongxin Guo, Shuting Guo, Chen Cai, Weidong Mi, Li Tong

Nan fang yi ke da xue xue bao = Journal of Southern Medical University March 20, 2026 DOI: 10.12122/j.issn.1673-4254.2026.03.02 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Peer reviewed
Sample size 150
Population Male C57BL/6J mice
Interventions Esketamine Saline
Topics Depression Esketamine
Keywords Glutamatergic neurons Medial prefrontal cortex
Key findings Esketamine's antidepressant effects in chronically stressed mice depend on activating glutamatergic neurons in the medial prefrontal cortex.

Abstract

To investigate the regulatory role of glutamatergic neurons in the medial prefrontal cortex (mPFC) in the antidepressant effects of esketamine. A total of 150 male C57BL/6J mice were randomly divided into 15 groups (n=10). The mice subjected to the chronic restraint stress (CRS), and those exhibiting depressive-like behaviors following CRS received either esketamine or saline treatment, and subsequent behavioral changes were evaluated. Depressive-like behaviors were assessed using tail suspension test (TST), forced swim test (FST), and sucrose preference test (SPT). The changes in neuronal activity within the mPFC were examined using c-Fos immunofluorescence staining. To explore the underlying mechanism, chemogenetic approaches were employed to specifically modulate the activity of mPFC glutamatergic neurons and examine how these manipulations influenced the effect of esketamine on behaviors of the mice. Compared with saline-treated CRS mice, the mice with esketamine treatment showed significantly reduced immobility time in TST and FST and increased sucrose preference rate. Immunofluorescence staining revealed significantly increased expression of c-Fos in glutamatergic neurons in esketamine-treated mice. Chemogenetic activation of mPFC glutamatergic neurons (hM3Dq group) significantly decreased immobility time of the mice in the TST and FST and increased their sucrose preference as compared with the mice in mCherry group (P<0.01), while inhibition of the mPFC glutamatergic neurons (hM4Di group) produced no significant effect. Among the mice treated with esketamine, those in hM4Di group exhibited significantly increased immobility time in TST and FST and decreased sucrose preference compared with those in mCherry group, while the mice in hM3Dq group showed no such changes. Esketamine produces antidepressant effects in mice with CRS by activating glutamatergic neurons in the mPFC.

Comparable studies

Other preclinical and animal studies on esketamine for depression, most cited first.

Study Year Design Participants
Low-dose S-ketamine exerts antidepressant-like effects via enhanced hippocampal synaptic plasticity in postpartum depression rats. Rat model of postpartum depression induced by reproductive hormone withdrawal 2022 Animal study
Antidepressant effects of esketamine via the BDNF/AKT/mTOR pathway in mice with postpartum depression and their offspring. Mice with postpartum depression and their offspring 2024 Animal study
Electroconvulsive therapy combined with esketamine improved depression through PI3K/AKT/GLT-1 pathway. Human patients with severe depression and a rat model of depression 2025 Randomized controlled trial and animal study n = 12
S-ketamine Alleviates Neuroinflammation and Attenuates Lipopolysaccharide-Induced Depression Via Targeting SIRT2. Lipopolysaccharide (LPS)-induced mouse model 2025 Animal study with in vitro and in vivo experiments
Esketamine alleviates LPS-induced depression-like behavior by activating Nrf2-mediated anti-inflammatory response in adolescent mice. Adolescent male C57BL/6J mice 2025 Preclinical experimental study

Explore topics

By condition and practice